# reload+after+2024-01-20 20:47:47.403000
address1§6 rue Alain Bombard
city§Saint-Herblain
zip§44800
country§France
phone§33 2 28 07 37 10
fax§33 2 28 07 37 11
website§https://valneva.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
fullTimeEmployees§719
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Thomas  Lingelbach', 'age': 60, 'title': 'President, CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 858605, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter  Buhler', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 569689, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Frederic  Jacotot', 'age': 57, 'title': 'VP of Legal & IP, General Counsel, and Corporate Secretary', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 327015, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Franck  Grimaud MBA', 'age': 56, 'title': 'Chief Business Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 426503, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Juan-Carlos  Jaramillo M.D.', 'age': 51, 'title': 'Chief Medical Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 517702, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Dipal  Patel', 'age': 48, 'title': 'Chief Commercial Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 831989, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Vincent  Dequenne', 'title': 'Chief Operating Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joshua  Drumm Ph.D.', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Laetitia  Bachelot-Fontaine', 'title': 'VP of Global Communications & European Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gerald  Strohmaier', 'title': 'Vice President of Human Resource', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§7
compensationRisk§10
shareHolderRightsRisk§9
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.809
priceToSalesTrailing12Months§3.2777145
currency§USD
dateShortInterest§1702598400
forwardEps§-0.35
exchange§NMS
quoteType§EQUITY
shortName§Valneva SE
longName§Valneva SE
firstTradeDateEpochUtc§1620221400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d5c4063e-b358-3b7a-83b2-0a4d4ac32777
gmtOffSetMilliseconds§-18000000
targetHighPrice§26.09
targetLowPrice§12.54
targetMeanPrice§20.19
targetMedianPrice§21.07
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§0.988
grossMargins§-0.2019
ebitdaMargins§-0.46803
trailingPegRatio§None
